Skip to main
BLSM

BLSM Stock Forecast & Price Target

BLSM Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BlossomHill Therapeutics is a promising biotech company, with a current market value of $30/share and a focus on developing drugs for NSCLC and other cancers. However, there are potential risks associated with regulatory approval and competition, and concerns about side effects for their lead drug, BH-30643. While they have potential for growth and mergers/acquisitions, profitability is not yet achieved and future capital raising may be necessary.

Bears say

BlossomHill Therapeutics is an early-stage biotech company with a business strategy focused on targeted "precision oncology" therapeutics aimed at developing differentiated small molecule medicines for cancer treatment. While the company's lead candidates show potential in addressing clinically validated and novel molecular targets, the competitive nature of the oncology market and the need for significant sales and marketing infrastructure may prove challenging for the company to overcome. Furthermore, the company's reliance on small molecule inhibitors and its focus on highly mutated cancers may limit its potential for widespread success in the market. Thus, there may be limited upside for shareholders, and the company's stock may continue to underperform.

BLSM has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Blossomhill Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Blossomhill Therapeutics Inc (BLSM) Forecast

Analysts have given BLSM a Buy based on their latest research and market trends.

According to 5 analysts, BLSM has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Blossomhill Therapeutics Inc (BLSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.